Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2010

View Archived Issues

TIGER-1 data detail potential of denufosol in cystic fibrosis

7TM Pharma reports encouraging phase I data on TM-38837

FSH receptor is a possible marker of several cancer types

Vertex Pharma enrolls additional cohort in phase II telaprevir/VX-222 trial

Furiex Pharma presents phase II data on JNJ-Q2

Trans-sodium crocetinate is beneficial in PAD-related intermittent claudication

Suven Life Sciences presents SUVN-F90101 and SUVN-F91201

AB Therapeutics reports data on two anticancer agents in model of NSCLC

MicroDose Therapeutx receives Therapeutic Discovery Project grants

ProtAffin receives funding from Austrian FFG to develop PA-401

Abbott describes analgesic effects of A-1048400

Nektar Therapeutics presents new tyrosine protein kinase inhibitor-oligomer conjugates

XenoPort discloses new GABA(B) receptor ligands

Karus Therapeutics claims new histone deacetylase inhibitors

Italian scientists discover new selective androgen receptor modulators

FDA approves Eisai's Halaven for late-stage breast cancer

Pozen achieves milestone under Vivomo partnership with AstraZeneca

BioWa licenses Potelligent technology to Agensys

StemCells files application in Switzerland for clinical trial of HuCNS-SC

FluCide Nanoviricides reduce viral load in model of lethal flu

Agios Pharma claims new activators of pyruvate kinase isozymes M1/M2

Health Canada approves Vitaros as first-line therapy for erectile dysfunction

Amakem receives Flemish IWT grant for ROCK inhibitor program in COPD

Merrion Pharma plans phase III study of Orazol in breast cancer

Horizon Pharma receives U.S. government grant for HZT-501

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 13, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...